Company
AboutTeamImpact
Science
Development ModelFocus AreasPipeline
Partnering
Business ModelPartners
Proof
Case StudiesContact
Home / Case Studies

Case studies.

Selected work, anonymised. Program detail and partner identities are available to qualified parties under NDA.

Technical Work

Formulations we have developed.

Selected programs across complex injectable platforms. Open a case for the challenge, approach and outcome. Program-level detail is available to qualified partners under NDA.

THEME

Poorly soluble actives

Most of the products we have developed address actives that are poorly soluble or insoluble in water.

ANTIEMETIC EMULSIONS

Solvent-free antiemetic emulsions

Two injectable emulsion presentations, each reformulated without organic solvent.

Read case
Challenge

Develop solvent-free versions of two established injectable emulsion presentations of an antiemetic.

Approach

Emulsion formulations designed to dispense with solvent while remaining physically stable and suitable for injection.

Outcome

Solvent-free formulations developed for both emulsion presentations.

Roles

Off Targets R&D led formulation development.

ACUTE-CARE EMULSION

Differentiated acute-care emulsion

A differentiated injectable emulsion for acute cardiovascular care.

Read case
Challenge

Create a differentiated version of an established acute-care emulsion, with a composition that stands apart from the reference while serving the same clinical purpose.

Approach

A reformulated emulsion composition that differs from the reference while serving the same clinical purpose.

Outcome

Differentiated formulation developed.

Roles

Off Targets R&D led formulation development.

NANOSUSPENSION

Injectable nanosuspension

A nanosuspension of a water-insoluble active for injection.

Read case
Challenge

Deliver a water-insoluble active as an injectable suspension at a concentration that solution formulations cannot reach.

Approach

Particle-size engineering to produce a nanometre-scale suspension of the active.

Outcome

Nanosuspension formulation developed.

Roles

Off Targets R&D led formulation development.

PARENTERAL NUTRITION

Lipid emulsions for parenteral nutrition

Generic equivalents of two established lipid emulsions, including a fish-oil-derived product.

Read case
Challenge

Match the composition and physical characteristics of two established lipid emulsions used in parenteral nutrition.

Approach

Formulations developed to match the references qualitatively and quantitatively, supported by characterisation of globule size and emulsion stability.

Outcome

Formulations developed.

Roles

Off Targets R&D led formulation development.

LONG-ACTING CNS

Long-acting antipsychotic injectables

Three long-acting programs, including a differentiated alternative to a leading product.

Read case
Challenge

Develop long-acting injectable versions of three established antipsychotics, including a differentiated alternative to a leading long-acting product.

Approach

Sustained-release depot formulations engineered for controlled release across the dosing interval.

Outcome

Three long-acting formulations developed.

Roles

Off Targets R&D led formulation development.

EXTENDED-RELEASE COMBINATION

Extended-release combination analgesic

A differentiated extended-release combination of a local anaesthetic and an anti-inflammatory.

Read case
Challenge

Deliver two actives with very different properties from a single extended-release depot for post-operative pain.

Approach

A differentiated depot formulation that co-delivers both actives.

Outcome

Differentiated formulation developed.

Roles

Off Targets R&D led formulation development.

ONCOLOGY NANOPARTICLE

Oncology injectable without its solubilising excipient

A cytotoxic reformulated to remove the excipient associated with hypersensitivity reactions.

Read case
Challenge

The active is poorly soluble in water, and the established product relies on a solubilising excipient associated with hypersensitivity reactions and the need for premedication.

Approach

A lipid-based nanoparticle formulation designed to carry the active without that excipient.

Outcome

Formulation developed that removes the excipient by design. Clinical benefit remains to be established.

Roles

Off Targets R&D led formulation development.

Delivery platforms we have worked with
EmulsionsNanosuspensionsLong-acting depotsMicrospheresIn-situ gelsLong-acting pre-filled syringesReady-to-use from vial formats

Descriptions are anonymised. “Developed” refers to formulation development and does not imply regulatory approval.

Partnership Models

How we have worked with partners.

The structures below have each been used in practice. Partner identities and terms are confidential.

THEME

Models we have operated

Co-development, territory-split licensing and strategic portfolio development, each with a different type of partner.

CO-DEVELOPMENT

Co-development with an API partner

Joint development with an active-ingredient manufacturer.

Read case
Situation

A program where the API source and the formulation expertise sat with different parties.

Model

Co-development with the API manufacturer as partner, combining its API capability with our formulation development.

Outcome

Structure operated in practice. Program detail and terms are confidential and available to qualified partners under NDA.

Roles

API partner: active ingredient. Off Targets: formulation development.

CO-DEVELOPMENT

Co-development with a CMO partner

Joint development with a contract manufacturer.

Read case
Situation

A program where manufacturing capability and formulation expertise sat with different parties.

Model

Co-development with a contract manufacturer as partner, aligning formulation development with manufacturing from an early stage.

Outcome

Structure operated in practice. Program detail and terms are confidential and available to qualified partners under NDA.

Roles

CMO partner: manufacturing. Off Targets: formulation development.

CO-DEVELOPMENT

Co-development with a virtual pharma partner

Joint development with a virtual pharmaceutical company.

Read case
Situation

A virtual pharmaceutical company with portfolio and market ambitions but no laboratory or formulation team of its own.

Model

Co-development with the virtual company as partner, with Off Targets providing the technical development capability.

Outcome

Structure operated in practice. Program detail and terms are confidential and available to qualified partners under NDA.

Roles

Virtual pharma partner: portfolio and commercial direction. Off Targets: development.

LICENCE AND BUILD

From licensee to portfolio

A licensee that went on to build a curated portfolio with us.

Read case
Situation

A company in-licensed one of our products.

Model

The relationship extended into joint development and joint investment in a curated portfolio of products for oncology and critical care.

Outcome

Structure operated in practice. Program detail and terms are confidential and available to qualified partners under NDA.

Roles

Licensee: joint investment. Off Targets: joint development.

SPLIT LICENSING

United States and Europe

One program licensed by territory across two regions.

Read case
Situation

A program with distinct commercial opportunities in the United States and Europe.

Model

Licensing split by territory, so that each region could be partnered separately.

Outcome

Structure operated in practice. Program detail and terms are confidential and available to qualified partners under NDA.

Roles

Licensees: commercialisation in their territory. Off Targets: development and licensing.

SPLIT LICENSING

United States and China

One program licensed by territory across two regions.

Read case
Situation

A program with distinct commercial opportunities in the United States and China.

Model

Licensing split by territory, so that each region could be partnered separately.

Outcome

Structure operated in practice. Program detail and terms are confidential and available to qualified partners under NDA.

Roles

Licensees: commercialisation in their territory. Off Targets: development and licensing.

STRATEGIC PORTFOLIO

Portfolio with a strategic financial partner

A portfolio of products developed with a financial partner.

Read case
Situation

A set of products that justified development as a portfolio rather than program by program.

Model

Strategic development of the portfolio in partnership with a strategic financial partner.

Outcome

Structure operated in practice. Program detail and terms are confidential and available to qualified partners under NDA.

Roles

Financial partner: strategic backing. Off Targets: development.

Next step

Discuss a program, licence or collaboration.